Clinical Applications

Brain Tumor

Magnetic Resonance Spectroscopy can aid in diagnosing and monitoring brain tumors by analyzing their chemical composition, distinguishing tumor types, tracking treatment progress, and detecting potential recurrence.

Traumatic Brain Injury

MRS offers insights into the evolving biochemical changes within the injured brain, such as reduced N-acetylaspartate (NAA) levels, which reflect neuronal damage, and the presence of lactate, which indicate ongoing metabolic stress. These metabolite alterations serve as critical markers, shedding light on the underlying mechanisms of TBI and guiding the development of tailored treatment strategies.

Parkinson’s Disease

Magnetic Resonance Spectroscopy (MRS) aids tracking Parkinson’s Disease progression by quantifying metabolite changes in the substantia nigra and other relevant brain regions. It can measure alterations in metabolite concentrations, such as N-acetylaspartate (NAA) and myo-Inositol (mI), offering valuable markers for measuring disease progression.

Multiple Sclerosis

Alzheimer’s Disease

MRS offers crucial insights into the underlying biochemical changes associated with Alzheimer’s Disease, such as reduced N-acetylaspartate (NAA) levels indicative of neuronal loss and increased myo-Inositol (mI) pointing to neuroinflammation. These specific metabolite markers enable healthcare professionals to monitor disease advancement and tailor interventions for Alzheimer’s patients as the condition evolves.

Epilepsy

MRS can play a crucial role in unraveling the intricate biochemical changes occurring in the epileptic brain. Elevated lactate levels point to heightened metabolic activity during seizures, while shifts in N-acetylaspartate (NAA) concentrations may indicate neuronal dysfunction. These unique metabolite profiles serve as invaluable indicators, enabling the tracking of epilepsy’s progression and the tailoring of personalized treatment approaches for individuals living with this neurological condition.

Schizophrenia

MRS offers key insights into the intricate biochemical changes associated with schizophrenia, such as alterations in glutamate and GABA levels, providing a window into the disorder’s neurochemical underpinnings. These specific metabolite profiles serve as valuable markers for tracking the evolution of schizophrenia and informing the development of tailored treatment approaches for affected individuals.

Hypoxic Ischemic Encephalopathy

MRS provides critical insights into the dynamic biochemical changes within the injured brain, such as elevated lactate and decreased N-acetylaspartate (NAA), indicating oxygen deprivation and neuronal damage, respectively. These specific metabolite profiles offer valuable markers for monitoring the evolution of HIE and guiding the customization of treatment strategies for affected individuals.